(Q37305489)

19 August 2017

The use of bevacizumab in refractory ovarian granulosa-cell carcinoma with symptomatic relief of ascites: a case report (English)

1 reference

19 August 2017

1 reference

1 reference

Joshua P Kesterson

1

1 reference

19 August 2017

Paulette Mhawech-Fauceglia

series ordinal

2

1 reference

19 August 2017

Shashikant Lele

series ordinal

3

1 reference

19 August 2017

language of work or name

English

0 references

publication date

16 August 2008

1 reference

19 August 2017

1 reference

19 August 2017

111

1 reference

19 August 2017

3

1 reference

19 August 2017

527-529

1 reference

Phase II trial of bevacizumab in persistent or recurrent epithelial ovarian cancer or primary peritoneal cancer: a Gynecologic Oncology Group Study

19 August 2017

1 reference

https://eutils.ncbi.nlm.nih.gov/entrez/eutils/elink.fcgi?dbfrom=pmc&linkname=pmc_refs_pubmed&retmode=json&id=5047386

The use of bevacizumab to palliate symptomatic ascites in patients with refractory ovarian carcinoma

6 September 2017

1 reference

https://eutils.ncbi.nlm.nih.gov/entrez/eutils/elink.fcgi?dbfrom=pmc&linkname=pmc_refs_pubmed&retmode=json&id=5047386

Vascular endothelial growth factor is a secreted angiogenic mitogen

6 September 2017

1 reference

https://eutils.ncbi.nlm.nih.gov/entrez/eutils/elink.fcgi?dbfrom=pmc&linkname=pmc_refs_pubmed&retmode=json&id=5047386

Evaluation of the antiangiogenic effect of Taxol in a human epithelial ovarian carcinoma cell line

6 September 2017

1 reference

https://eutils.ncbi.nlm.nih.gov/entrez/eutils/elink.fcgi?dbfrom=pmc&linkname=pmc_refs_pubmed&retmode=json&id=5047386

Glucose metabolism and angiogenesis in granulosa cell tumors of the ovary: activation of Akt, expression of M2PK, TKTL1 and VEGF.

14 September 2017

1 reference

https://eutils.ncbi.nlm.nih.gov/entrez/eutils/elink.fcgi?dbfrom=pmc&linkname=pmc_refs_pubmed&retmode=json&id=5047386

Phase II study of bevacizumab in patients with platinum-resistant ovarian cancer or peritoneal serous cancer

2 September 2018

1 reference

https://eutils.ncbi.nlm.nih.gov/entrez/eutils/elink.fcgi?dbfrom=pmc&linkname=pmc_refs_pubmed&retmode=json&id=5047386

Salvage bevacizumab (rhuMAB VEGF)-based therapy after multiple prior cytotoxic regimens in advanced refractory epithelial ovarian cancer

2 September 2018

1 reference

https://eutils.ncbi.nlm.nih.gov/entrez/eutils/elink.fcgi?dbfrom=pmc&linkname=pmc_refs_pubmed&retmode=json&id=5047386

Bevacizumab and weekly taxane chemotherapy demonstrates activity in refractory ovarian cancer

2 September 2018

1 reference

https://eutils.ncbi.nlm.nih.gov/entrez/eutils/elink.fcgi?dbfrom=pmc&linkname=pmc_refs_pubmed&retmode=json&id=5047386

The role of bevacizumab in ovarian cancer--an evolving story

2 September 2018

1 reference

Crossref

https://api.crossref.org/works/10.1016%2FJ.YGYNO.2008.07.015

10.1016/J.YGYNO.2008.07.015

7 January 2021

Identifiers

DOI

1 reference

19 August 2017

1 reference

19 August 2017

PubMed publication ID

18710781

1 reference